Denise Scots-Knight - 25 Jan 2025 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role
Chief Executive Officer
Signature
/s/ Christine Fox, by power of attorney
Issuer symbol
MREO
Transactions as of
25 Jan 2025
Transactions value $
$0
Form type
4
Filing time
28 Jan 2025, 16:05:03 UTC
Previous filing
03 Dec 2024
Next filing
02 Dec 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MREO Share Options (Right to buy) Award $0 +825K $0.00 825K 25 Jan 2025 American Depository Shares 825K $2.91 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this share option will vest and become exercisable on January 25, 2026, with the remainder vesting in equal monthly installments for the three years thereafter.
F2 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.